| Literature DB >> 25748907 |
Abstract
Using conventional drug discovery and novel synthetic biology approaches, some investigators and companies are mining our resident microbes and their metabolites for targets in small-molecule drug programs. Ken Garber reports.Entities:
Mesh:
Year: 2015 PMID: 25748907 DOI: 10.1038/nbt.3161
Source DB: PubMed Journal: Nat Biotechnol ISSN: 1087-0156 Impact factor: 54.908